We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Indivior Plc | INDV | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 25.50 | 2.65% | 987.00 | 16:35:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,001.00 | 958.00 | 1,013.00 | 987.00 | 961.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 17/7/2024 08:01 by casholaa "Q2 and H1 2024 results on July 25th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website" |
Posted at 15/7/2024 10:04 by gregmorg I too thought there must be some dodgy dealings but a look at the presentation of 4th June to US investors has made me think otherwise . Within that presentation it stood out that there were no text slides on Perseris or comment . Lots of slides and comment on Sublocade and Opvee,(the new instant hit product) but nothing on the other revenue generator.The odd historic data slide and that’s it. Strange! The absence was really glaring and would have caused good analysts to dig a lot deeper as the company was no doubt analysing and struggling with a corporate decision.Avoiding the issue has to raise alarm bells! I admit I completely missed the omission at the time. Not happy at all at the sequence of events but looking back , damn it, I can see pointers |
Posted at 09/7/2024 11:55 by grupo Indivior cuts jobs and discontinues sales of schizophrenia medicationBy This Is Money DAILY MAIL Updated: 11:38 BST, 9 July 2024 Indivior shares nosedived on Tuesday after the drugmaker slashed its profit guidance and revealed it would discontinue sales of a schizophrenia drug. The group, which switched its primary listing to the US last month but continues to trade on the FTSE 250, told investors it would cut 130 jobs related to the discontinuation of sales of Perseris. Mark Crossley, chief executive, said expectations of higher payer management related to Perseris made production 'no longer financially viable' and so it would be discontinued. Indivior will continue to supply Perseris to avoid patient care disruption for the foreseeable future, but said it will no longer deploy a dedicated sales force. Indivior shares were down 38.7 per cent to 723.5p in early trading in London on Tuesday, having lost around 50 per cent over the last year. The firm also told shareholders that net revenue for its opioid disorder drug Sublocade continues to be weak, due primarily to the elimination of Covid-19 emergency measures related to automatic Medicaid coverage renewals in the US. Crossley said: 'As we look to the second half of the year, the US government has extended renewal allowances for certain States which will further delay the annualisation of this significant headwind. 'We are therefore reducing our FY 2024 guidance to reflect these impacts.' But Crossley added that Indivior remains 'firm in our conviction that Sublocade's unique profile to address high-powered synthetic opioids', such as fentanyl, provides the group with 'a tremendous opportunity to meet the growing and changing needs of patients'. He said: 'As a result, we continue to be confident that Sublocade will achieve a net revenue run rate of $1billion as we exit 2025 and ultimately meet our target of greater than $1.5billion in peak annual net revenue, underpinning the successful delivery of our medium-term profitable growth ambitions.' |
Posted at 03/7/2024 07:36 by maywillow PERHAPS 30th August |
Posted at 23/4/2024 14:49 by gregmorg Well Dealy,Overall you may well be right re US valuations versus UK valuations. Certainly, David Schwimmer CEO of LSEG Group Plc (of which the London Stock Exchange is a small part) has also stated very similar sentiment. However, this hasn't stopped the UK media( plus others) and many UK companies and senior executives indicating otherwise and expressing frustration,if not actually indicating they are actively looking at possible relocation. Obviously there can be several agenda's here , and that I accept. Unfortunately those intimately involved with markets seem not to be able to address the issues very well. Possibly, its just this stage we have reached within a normal stock market cycle although the bigger and more liquid market place argument is powerful. As an ordinary investor here I just find it very frustrating. |
Posted at 23/4/2024 10:03 by gregmorg Purely speculation on my part but I do wonder whether the change in listing status ,resulting in a lesser UK market status is causing a near term outflow of UK investors. What it does for Indivior's UK indices standing I just don't know. Maybe it also takes time for the US Nasdaq main listing investor base to develop let alone build up a US indices momentum .Hence little current forward optimism.Anything else well ,we will soon find out! The early half US Nasdaq additional listing has, of course, been a complete dud-- well, for the majority of investors anyway! At times I wonder what quality of capital markets advisers these chaps have-let alone in house stock market awareness! |
Posted at 22/2/2024 15:10 by casholaa In fairness to them, they've hived off money for the litigation so it doesn't distort net cash, they recognize that it's mainly a US market-driven company with mainly US investors, they are expanding globally, they are not a one-trick pony, they have been succeeding on the revenue front and return value to shareholders through buybacks for the time being.*they also pointed out that they only recently started sales through pharmacy/private doctor dispensers *global company in the making, we just happen to be poorer than our US counterparts |
Posted at 05/12/2023 16:08 by waldron Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)05/12/2023 2:06pm UK Regulatory (RNS & others) Tuesday 5 December 2023 TIDMINDV RNS Number : 7595V Indivior Prevails in Striking Representative Claims from UK Shareholder Action Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant. In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser. After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here . Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings. Wirral may seek permission to appeal the Court's judgment. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/com This release is being made by Kathryn Hudson, Company Secretary Indivior PLC. Media Contacts : US Media : Cassie France-Kelly Vice President, Communications Indivior PLC Tel: 804-724-0327 UK Media : Teneo Tel: +44 207-353-4200 Investors and Analysts : Jason Thompson Vice President, Investor Relations Indivior PLC Tel: 804-402-7123 Tim Owens Director, Investor Relations Indivior PLC Tel: 804-263-3978 -ends- (END) Dow Jones Newswires December 05, 2023 09:06 ET (14:06 GMT) |
Posted at 09/11/2023 07:38 by ariane SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: Participants may access the presentation telephonically by registering with the following link: [...] |
Posted at 24/5/2023 06:47 by steeplejack Executives see the US as an environment that embraces higher growth, while they bemoan the lack of interest from UK-based investors in their home market, particularly pension funds that have increasingly shunned British stocks over the past two decades.“There are no domestic equity investors here — everything else is a symptom,” said Michael Tory, founder of advisory firm Ondra Partners. “It’s not about the listing rules, the governance or the free float requirements. Global investors look to domestic investors for the signal to validate the investment, and that local signal has simply flickered out.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
